This activity is sponsored by

This activity is supported by educational grants from

Robert L. Fine, MD – Chair
Irving Associate Professor of Medicine
Director of Experimental Therapeutics Program
Division of Hematology/Oncology
Director of Medical Oncology in the Pancreas Center at Columbia
NewYork-Presbyterian-Columbia University Medical Centers
New York, New York

Samir M. Hanash, MD, PhD
Full Member
Public Health Sciences Division
Molecular Diagnostics
Fred Hutchinson Cancer Research Center
Seattle, Washington

Learning Objectives
Upon completion of this educational activity, participants should be better able to:

• Understand the genetic and molecular basis of pancreatic cancer
• Discuss the role of SPARC expression and implications on tumor response to nanoparticle albumin-bound therapies
• Explain the rationale for the development and use of new therapeutic approaches in pancreatic cancer
• Discuss the clinical implications of pivotal clinical trials involving taxane-based therapies in pancreatic cancer
• Analyze future treatment strategies and clinical trials needed to advance therapeutic progress in pancreatic cancer

Target Audience
The target audience for the program includes medical oncologists, gastroenterologists, pathologists, and allied healthcare professionals caring for patients with pancreatic cancer.

Statement of Need
In spite of the acceptance of gemcitabine by most as a standard first-line agent for the treatment of advanced pancreatic cancer, novel therapies and combinations are urgently needed as this disease has one of the lowest survival rates of all cancers. The growing understanding of the molecular basis of pancreatic cancer as well as the recent introduction of targeted therapeutic agents has prompted studies of novel agents that have the potential to improve on existing treatments. Although incremental progress has been made in the treatment of pancreatic cancer, new drugs and approaches are critically needed as there are no standards currently accepted for treatment of this disease and prognosis remains very disappointing overall.

ACCREDITATION INFORMATION

PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
	Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Educational Concepts Group, LLC designates this continuing education activity for 2.0  contact hours (0.20 CEUs). (UAN 0199-0000-09-096-H01-P).

Type of activity: Knowledge-based

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period February 8, 2010 through February 7, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

The following faculty members have declared relevant financial relationships:

ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Abraxis BioScience, LLC, Lilly USA, LLC, and OSI Pharmaceuticals, Inc.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CME/CE INQUIRIES
For further information, please contact:
Educational Concepts Group, LLC 
1300 Parkwood Circle SE, Suite 325 | Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.